Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
DEA proposes to revoke exemption status for certain nonnarcotic butalbital products, reclassifying them as controlled substances subject to full DEA regulations.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Manufacturers, distributors, and dispensers of the affected butalbital products currently listed on DEA's Table of Exempted Prescription Products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; comment period deadline is likely 60 days from publication (check the Federal Register notice).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The exemption status for inactive butalbital products is proposed for removal, meaning these products would become controlled substances requiring DEA registration, quotas, and reporting.
Who it affects
Manufacturers, distributors, and dispensers of the affected butalbital products currently listed on DEA's Table of Exempted Prescription Products.
What you must do
Review the list of affected products in the proposal and prepare to obtain DEA registration and quota for manufacturing or handling these substances.
Deadline
Not specified in the excerpt; comment period deadline is likely 60 days from publication (check the Federal Register notice).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial